If the answer is 'Yes', you might be a candidate to participate in a clinical study on the treatment of Critical Limb Ischemia (CLI). In this study named ‘Salamander’, a novel cell therapy will be tested.

Critical limb Ischemia is a severe stage of Peripheral Arterial Disease (PAD). Symptoms of CLI include:

    A severe burning pain in legs and feet that continues even during rest
    Skin turning pale, shiny, smooth and dry
    Wounds and ulcers (open sores) on feet and legs that do not heal
    Loss of muscle mass in your legs
    Skin on toes or lower limbs becoming cold and numb, turning red and then black, and/or beginning to swell and produce foul-smelling pus, causing severe pain (gangrene)

The study will evaluate the effects of a new cell therapy that is prepared using your own bone marrow. This study involves an experimental product called REX-001 and a placebo. There is a 33% probability that you will receive the placebo in this study. At the point when all patients participating in the study have had a follow up after 12 months, patients assigned to the placebo group will be offered treatment with REX-001, the experimental product.

REX-001 consists of cells from the patient’s own bone marrow. It is expected to strengthen the quality of existing blood vessels and stimulate the formation of new blood vessels. As a result, the blood flow in the patient’s leg could be significantly improved. The pain at rest that patients experience could be resolved and wounds on toes or feet could heal.

Click on Critical Limb Ischemia to learn more about the disease. Or click on Study Information to learn more about this study.


Check now whether you could participate in this study and learn about the participating centers.

Check now!